In particular, antagonists of A2AR are just occurring to be deployed into oncology, which can block the interaction between ADO and A2AR, thereby alleviating tumor immunosuppression and facilitating the antitumor immune response19,20. The gene discussed is ADO; the disease is neoplasm.